Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025
Cannara Biotech (OTCQB:LOVFF) reported record-breaking financial results for Q3 2025, with total revenues reaching $27.3 million, a 40% increase year-over-year. The company achieved its seventeenth consecutive quarter of positive Adjusted EBITDA, which rose 173% to $7.6 million.
Key highlights include a 110% increase in gross profit to $12.1 million, improved gross margins of 44% (up from 29%), and record operating cash flow of $13.9 million. The company achieved a significant 26% yield improvement across its facilities, increasing annual capacity from 39,500 kg to 50,000 kg, meeting its Fiscal 2026 target ahead of schedule.
Additionally, Cannara secured approval for 5 SKUs in Quebec's upcoming vape category launch, representing 20% of all accepted in-store SKUs, and reduced its BMO credit facility interest rate to below 6%.
[ "Record revenue of $27.3M, up 40% year-over-year", "Gross profit increased 110% to $12.1M with margins expanding to 44%", "Record Adjusted EBITDA of $7.6M, up 173% year-over-year", "26% yield improvement achieved without additional capital expenditures", "Operating cash flow increased 221% to $13.9M", "Secured 20% market share in Quebec's new vape category", "Credit facility interest rate reduced to below 6%", "Earnings per share increased to $0.05 from $0.02 year-over-year" ]Cannara Biotech (OTCQB:LOVFF) ha riportato risultati finanziari record nel terzo trimestre del 2025, con ricavi totali che hanno raggiunto 27,3 milioni di dollari, segnando un aumento del 40% rispetto all'anno precedente. L'azienda ha registrato il suo diciassettesimo trimestre consecutivo di EBITDA rettificato positivo, salito del 173% a 7,6 milioni di dollari.
I punti salienti includono un aumento del 110% del profitto lordo a 12,1 milioni di dollari, un miglioramento dei margini lordi al 44% (dal 29%) e un flusso di cassa operativo record di 13,9 milioni di dollari. L'azienda ha ottenuto un significativo miglioramento del rendimento del 26% nelle sue strutture, aumentando la capacità annua da 39.500 kg a 50.000 kg, raggiungendo in anticipo l'obiettivo fiscale 2026.
Inoltre, Cannara ha ottenuto l'approvazione per 5 SKU nel lancio imminente della categoria vape in Quebec, rappresentando il 20% di tutti gli SKU accettati nei negozi, e ha ridotto il tasso di interesse sulla linea di credito BMO al di sotto del 6%.
Cannara Biotech (OTCQB:LOVFF) reportó resultados financieros récord en el tercer trimestre de 2025, con ingresos totales que alcanzaron los 27,3 millones de dólares, un aumento del 40% interanual. La compañía logró su decimoséptimo trimestre consecutivo de EBITDA ajustado positivo, que aumentó un 173% hasta los 7,6 millones de dólares.
Los aspectos destacados incluyen un aumento del 110% en la ganancia bruta hasta 12,1 millones de dólares, márgenes brutos mejorados al 44% (desde el 29%) y un flujo de caja operativo récord de 13,9 millones de dólares. La empresa logró una mejora significativa del 26% en el rendimiento en sus instalaciones, aumentando la capacidad anual de 39.500 kg a 50.000 kg, cumpliendo con su objetivo fiscal para 2026 antes de lo previsto.
Además, Cannara aseguró la aprobación de 5 SKUs en el próximo lanzamiento de la categoría vape en Quebec, representando el 20% de todos los SKUs aceptados en tienda, y redujo la tasa de interés de su línea de crédito BMO a menos del 6%.
Cannara Biotech (OTCQB:LOVFF)는 2025년 3분기 실적에서 총 매출 2,730만 달러를 기록하며 전년 대비 40% 증가한 사상 최고의 성과를 보고했습니다. 회사는 17분기 연속으로 조정 EBITDA 흑자를 달성했으며, 이는 173% 증가한 760만 달러에 달했습니다.
주요 성과로는 총이익이 110% 증가하여 1,210만 달러에 이르렀고, 총마진이 29%에서 44%로 개선되었으며, 운영 현금 흐름은 1,390만 달러로 사상 최고치를 기록했습니다. 회사는 시설 전반에 걸쳐 수율을 26% 향상시켜 연간 생산능력을 39,500kg에서 50,000kg으로 늘리며 2026 회계연도 목표를 앞당겨 달성했습니다.
또한 Cannara는 퀘벡의 신규 베이프 카테고리 출시에서 5개 SKU 승인을 확보하여 매장 내 승인된 SKU의 20%를 차지했으며, BMO 신용 시설의 이자율을 6% 이하로 낮췄습니다.
Cannara Biotech (OTCQB:LOVFF) a annoncé des résultats financiers record pour le troisième trimestre 2025, avec un chiffre d'affaires total atteignant 27,3 millions de dollars, soit une augmentation de 40 % par rapport à l'année précédente. La société a enregistré son dix-septième trimestre consécutif d'EBITDA ajusté positif, en hausse de 173 % à 7,6 millions de dollars.
Les points clés comprennent une augmentation de 110 % du bénéfice brut à 12,1 millions de dollars, une amélioration des marges brutes à 44 % (contre 29 %) et un flux de trésorerie opérationnel record de 13,9 millions de dollars. La société a réalisé une amélioration significative du rendement de 26 % dans ses installations, augmentant la capacité annuelle de 39 500 kg à 50 000 kg, atteignant ainsi son objectif fiscal 2026 en avance sur le calendrier.
De plus, Cannara a obtenu l'approbation de 5 références (SKUs) pour le lancement prochain de la catégorie vape au Québec, représentant 20 % de toutes les références acceptées en magasin, et a réduit le taux d'intérêt de sa facilité de crédit BMO à moins de 6 %.
Cannara Biotech (OTCQB:LOVFF) meldete rekordverdächtige Finanzergebnisse für das dritte Quartal 2025 mit einem Gesamtumsatz von 27,3 Millionen US-Dollar, was einem Anstieg von 40 % gegenüber dem Vorjahr entspricht. Das Unternehmen erzielte sein siebzehntes aufeinanderfolgendes Quartal mit positivem bereinigtem EBITDA, das um 173 % auf 7,6 Millionen US-Dollar stieg.
Zu den wichtigsten Highlights zählen ein 110%iger Anstieg des Bruttogewinns auf 12,1 Millionen US-Dollar, verbesserte Bruttomargen von 44 % (vorher 29 %) und ein Rekordbetriebscashflow von 13,9 Millionen US-Dollar. Das Unternehmen erzielte eine signifikante 26%ige Steigerung der Ausbeute in seinen Anlagen, wodurch die Jahreskapazität von 39.500 kg auf 50.000 kg erhöht wurde und das Ziel für das Geschäftsjahr 2026 vorzeitig erreicht wurde.
Zusätzlich sicherte sich Cannara die Zulassung für 5 SKUs beim bevorstehenden Start der Vape-Kategorie in Quebec, was 20 % aller im Laden akzeptierten SKUs entspricht, und senkte den Zinssatz seiner BMO-Kreditfazilität auf unter 6 %.
- None.
- Quebec market share declined 4% quarter-over-quarter to 12.3%
- Alberta market share decreased 16.1% year-over-year to 2.6%
- Nova Scotia market share dropped 20% quarter-over-quarter to 0.4%
- Record Revenue: Total revenues, net of excise taxes increased to
$27.3 million in Q3 2025, representing a40% increase over the prior year period. - Record Profitability: Gross profit before fair value adjustments rose to
$12.1 million in Q3 2025, representing a110% increase over the prior year period. Gross margin before fair value adjustments rose to44% in Q3 2025, from29% in the prior year period. - Record Adjusted EBITDA and Adjusted EBITDA Margin: Delivered seventeenth consecutive quarter of positive Adjusted EBITDA, which increased to a record high of
$7.6 million in Q3 20251, representing a173% increase over the prior year period. Delivered Adjusted EBITDA margin rose to28% in Q3 2025, from14% in the prior year period. - Record Operating and Free Cash Flow: Delivered
$13.9 million of operating cash flow and$11.7 million of free cash flow1 in Q3 2025, representing a221% and841% respective increase over the prior year period. - Yield Improvement: Extensive research and development on optimizing cultivation procedures has driven a
26% yield improvement across Cannara’s facilities, increasing current annual capacity from 39,500 kg to 50,000 kg — allowing the Company to achieve its Fiscal 2026 cultivation target a full year ahead of schedule without additional capital expenditures. - Quebec Vape Launch: Received 5 accepted SKUs, pending final procedural steps, for the Quebec provincial vape category launch, representing
20% of all accepted in-store SKUs by the SQDC. - Reduced Interest Rate: Lowered interest rate on BMO credit facility by 50 basis points and a further 25 basis points subsequent to quarter-end. Cannara’s cost of debt on its credit facility is now below
6% .
All financial results are reported in Canadian dollars, unless otherwise stated.
MONTREAL, July 28, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its financial and operating results for the three and nine-month periods ended May 31, 2025.
The full set of interim condensed consolidated financial statements for the three and nine-month periods ended May 31, 2025, and the accompanying Management’s Discussion and Analysis can be accessed by visiting the Company’s website at investors.cannara.ca, or by accessing the Company’s SEDAR+ profile at www.sedarplus.ca.
"Fiscal Q3 2025 represents another record-breaking quarter for Cannara, producing records for revenue, gross profit, gross margin, adjusted EBITDA, adjusted EBITDA margin, operating cash flow, and free cash flow, showcasing the successful execution of our long-term business strategy, as well as our industry leadership,” stated Zohar Krivorot, President & Chief Executive Officer of Cannara.
“In addition to our stellar operating results, we have achieved two very significant milestones within our business. First, for the upcoming launch of Québec’s high-demand vape category, the acceptance of 5 Cannara SKUs, pending final procedural steps, representing
1 Please refer to the “Non-GAAP Measures and Other Financial Measures” section of this news release for corresponding definitions.
“I would like to sincerely congratulate our commercial and operational teams on their execution, and look forward to delivering on these new opportunities,” concluded Mr. Krivorot.
"Our record-breaking financial performance in Fiscal Q3 2025 highlights the strength of Cannara Biotech’s strategy, and our absolute focus on disciplined cost management and evolving operational competencies while continuing to profitably grow the business,” commented Nicholas Sosiak, Chief Financial Officer of Cannara. “Gross profit before fair value adjustments rose
“We delivered our seventeenth consecutive quarter of positive Adjusted EBITDA, generating a record-high of
“This industry leading profitability profile reflects our extremely focused leadership, best-in-class production facilities, and many inherent competitive advantages within our operating platform, and will allow us to further strengthen our financial position ahead of our significant, low-cost, high ROI opportunities present within our existing footprint.” concluded Mr. Sosiak.
FISCAL Q3 2025 EARNINGS WEBCAST
Cannara Biotech’s CFO, Nicholas Sosiak, will host an earnings webcast today, Monday, July 28, 2025, at 11 a.m. ET consisting of prepared remarks followed by a question-and-answer session.
A Media Snippet accompanying this announcement is available by clicking on this link.
Participants can find the live webcast here or on the Cannara Biotech website at https://www.cannara.ca/investors/company-events/. For interested individuals unable to join, the event will be archived on the company’s website.
Investors are encouraged to submit questions in advance to investors@cannara.ca. While live questions will be accepted during the session, priority will be given to those submitted by email.
FISCAL Q3 2025 FINANCIAL HIGHLIGHTS
Q3 2025 vs Q3 2024 Comparable Period Highlights
- Gross cannabis revenues before excise taxes increased to
$37.8 million in Q3 2025 from$26.2 million in Q3 2024, a$11.6 million or44% , increase. The increase is attributable to increased market penetration in existing markets, entry into new markets and the addition of new genetics and products in its portfolio increasing overall sales generation; - Total revenues, net of excise taxes, increased to
$27.3 million in Q3 2025 from$19.5 million in Q3 2024, a$7.8 million or40% increase; - Gross profit before fair value adjustments rose to
$12.1 million in Q3 2025, up110% from$5.7 million in Q3 2024. This strong growth was driven by expanded production capacity following the activation of the 10th grow zone in Q1 2025 and the 11th and 12th grow zones in Q3 2025. In addition, continuous enhancements to cultivation practices significantly improved operational efficiency and boosted yields, which was also supported by the Company’s pheno-hunt program, which identified higher yielding genetics; - Gross profit percentage before fair value adjustments increased to
44% in Q3 2025 from29% in Q3 2024, driven by increased production capacity as well as cultivation and post-processing operational improvements and optimization; - Operating income reached
$6.8 million in Q3 2025, compared to an operating income of$3.6 million in Q3 2024. The improvement was driven by higher sales, lower production costs, which was partially offset by higher sales and marketing expenses year-over-year; - Net income before income tax was
$5.8 million in Q3 2025, compared to$2.0 million in Q3 2024. This marks a positive milestone and underscores the continued success and profitability of the Company; - Adjusted EBITDA increased by
173% , from$2.8 million in Q3 2024 to$7.6 million in Q3 20252; - The Company generated operating cash flow of
$13.9 million in Q3 2025, compared to$4.3 million in Q3 2024; - Free cash flow for Q3 2025 increased by
$10.5 million , from$1.2 million in Q3 2024 to$11.7 million in Q3 2025 2; - Generated earnings per share of
$0.05 in Q3 2025 compared to$0.02 in Q3 2024.
Q3 2025 YTD vs Q3 2024 YTD Highlights
- Gross cannabis revenues before excise taxes rose to
$109.5 million for the year-to-date period ending Q3 2025, up from$78.8 million in the same period in 2024, an increase of$30.7 million or39% . This growth reflects deeper market penetration across existing provinces, successful entry into new markets, and the expansion of the Company’s product portfolio through the launch of new genetics and SKUs that have strengthened sales performance; - Total revenues, net of excise taxes, increased to
$79 million in Q3 2025 YTD from$58.7 million in Q3 2024 YTD, a$20.3 million or35% increase; - Gross profit, before fair value adjustments, increased to
$32.7 million in Q3 2025 YTD from$20.8 million in Q3 2024 YTD, a$11.8 million or57% increase. This increase is attributable to increase production capacity combined with the efficiencies generated from the scale of the operations and various improvements in operations from cultivation to post processing; - Gross profit percentage before fair value adjustments in Q3 2025 YTD was
41% an increase of6% compared to35% in Q3 2024 YTD reflecting our capabilities in economies of scale; - Operating income of
$16.9 million in Q3 2025 YTD compared to an operating income of$5.0 million in Q3 2024 YTD, due to increase in sales and reduction in production costs offset by increased sales and marketing costs compared to the prior year period; - Net income before income tax was of
$13.6 million in Q3 2025 YTD compared to net income of$0.7 million in Q3 2024 YTD; - Adjusted EBITDA increased by 81 %, from
$11.4 million in Q3 2024 YTD to$20.7 million in Q3 2025 YTD2; - The Company generated operating cash flow amounting to
$17.2 million in Q3 2025 YTD compared to$7.5 million in Q3 2024 YTD; - Free cash flow for Q3 2025 YTD increased by
$11.8 million , from$0.5 million in Q3 2024 YTD to$12.3 million in Q3 2025 YTD2; - Generated earnings per share of
$0.11 in Q3 2025 YTD compared to earnings per share of$0.01 in Q3 2024 YTD.
2 Please refer to the “Non-GAAP Measures and Other Financial Measures” section of this news release for corresponding definitions.
FISCAL Q3 2025 OPERATIONAL HIGHLIGHTS
Capacity Expansion and Yield Optimization
During the quarter, the Company maintained a strong focus on execution, scaling its operations and supply chain to support continued growth in sales and market share across Canada. As part of its 2025 expansion plan, Cannara advanced the activation of two additional grow rooms at its Valleyfield facility. These rooms came online in May and June 2025, adding 50,000 sq. ft. of additional capacity. In parallel, the Company achieved a major operational milestone by optimizing its cultivation cycle time through its ongoing and extensive research and development efforts. These improvements increased both yield and harvest frequency, enabling Cannara to increase its production capacity from 39,500 kg to 50,000 kg annually reaching its Fiscal 2026 production target one year ahead of schedule, while maintaining a disciplined, margin-focused growth strategy.
While the Valleyfield Facility has only realized half of its full 24-zone capacity, the Company’s strategy is to scale production gradually, in line with market demand, rather than pursuing rapid volume growth at the expense of profitability. This disciplined approach, coupled with investments in sales and marketing, positions Cannara to strengthen brand recognition and loyalty across its three flagship brands — Tribal, Nugz, and Orchid CBD — while protecting margins in an increasingly competitive landscape.
Innovating for Market Leadership
By growing successful product lines and strengthening its position within priority categories, Cannara is effectively capturing additional market share and reinforcing its leadership through disciplined category management and targeted innovation. Launch highlights of Cannara’s product portfolio for Q3 2025 include:
- Quebec Tribal G Mint Trifecta infused pre-rolls (unique sub
30% THC offering for Quebec as per provincial regulations); - Nugz Neon Bubble Bath infused pre-rolls;
- Nugz Neon Bubble Bath all-in-one cured resin vape; and
- Nugz Meat Pie dried flower.
For Q4 2025, the Company has secured approval for 11 new product launches: 10 in Ontario and 1 in Quebec. These include two new genetics, Waygu Delight and Porto Leche, and Cannara’s first accessory listing with the SQDC, the Häpple glass hash pipe. Upcoming new product launches include:
- Nugz Waygu 7g dried flower and 7 x 0.5g multipack pre-rolls;
- Tribal Porto Leche 3.5g dried flower and 5 x 0.6g multipack pre-roll;
- Nugz Guava Jam 7 x 0.5g multipack pre-rolls;
- Tribal G Mint Supernova all-in-one live resin vape;
- Tribal Galactic Rntz Supernova all-in-one live resin vape;
- Tribal Triple Burger Supernova all-in-one live resin vape;
- Tribal Bubble Up Trifecta infused pre-rolls;
- Tribal Neon Sunshine Genetic Pro 510 vape battery; and
- Häpple glass hash pipe.
Quebec Vape Category Launch
Following the SQDC’s recent announcement to open the vape category in Quebec starting November 2025, in July 2025, Cannara secured approval, pending final procedural steps, to launch 5 live resin and rosin vape cartridges formulated to deliver a full-spectrum experience, without fillers or distillate and while remaining under
Strengthening Leadership Across Canada
The table below presents the Company’s national market share for the most recent completed quarter, along with a comparison to the previous quarter. Cannara’s recent performance across various provinces highlights its continued successful performance across all markets demonstrating its ability to capture market share from its competitors.
Q3 2025 vs Q2 2025 Market Share by Province3
Quarter over Quarter
The table below presents the Company’s national and provincial market share for the most recent completed quarter, along with a comparison to the previous quarter.
| Province | Q3 2025 | Q2 2025 | Variance |
| Quebec | - | ||
| Ontario | |||
| Alberta | - | ||
| British Columbia | + | ||
| Saskatchewan | + | ||
| Manitoba | |||
| Nova Scotia | - |
Q3 2025 vs Q3 2024 Market Share by Province3
Comparable Period
The table below presents the Company’s national and provincial market share for the most recent completed quarter, along with a comparison to the same period of prior year.
| Province | Q3 2025 | Q3 2024 | Variance |
| Quebec | + | ||
| Ontario | |||
| Alberta | - | ||
| British Columbia | + | ||
| Saskatchewan | + | ||
| Manitoba | NA | NA | |
| Nova Scotia | NA | NA |
3 As reported by Hifyre data for the periods of March 2024 to May 2024, December 2024 to February 2025 and March 2025 to May 2025 in all listed provinces excluding Quebec where Weed Crawler was deemed more accurate, and Nova Scotia where NSLC wholesale data was deemed to be more accurate.
SELECTED FINANCIAL HIGHLIGHTS
| Three-month periods ended | Nine-month periods ended | ||||||||
| Selected Financial Highlights | May 31, 2025 | May 31, 2024 | May 31, 2025 | May 31, 2024 | |||||
| Financial Summary | |||||||||
| Net revenue1 | $ | 27,268,032 | $ | 19,475,137 | $ | 78,681,871 | $ | 58,563,040 | |
| Other income | 64,853 | 69,779 | 307,585 | 148,373 | |||||
| Total revenues | 27,332,885 | 19,544,916 | 78,989,456 | 58,711,413 | |||||
| Gross profit, before fair value adjustments | 12,057,743 | 5,747,047 | 32,672,116 | 20,824,040 | |||||
| Gross profit | 12,882,763 | 6,958,256 | 35,017,236 | 19,334,110 | |||||
| Operating expenses | 6,118,036 | 3,404,212 | 18,143,204 | 14,300,967 | |||||
| Operating income | 6,764,727 | 3,554,044 | 16,874,032 | 5,033,143 | |||||
| Net finance expense | 972,377 | 1,530,658 | 3,318,384 | 4,349,098 | |||||
| Net income before income taxes | 5,792,350 | 2,023,386 | 13,555,648 | 684,045 | |||||
| Net income | 4,142,169 | 2,023,386 | 9,762,573 | 684,045 | |||||
| Adjusted EBITDA2 | 7,600,525 | 2,776,397 | 20,684,044 | 11,447,529 | |||||
| Percentages of Total revenues | |||||||||
| Gross profit, before fair value adjustments as a percentage of Total revenues3 | |||||||||
| Gross profit as a percentage of Total revenues4 | |||||||||
| Operating income as a percentage of Total revenues5 | |||||||||
| Net income before income taxes as a percentage of Total revenues6 | |||||||||
| Net income as a percentage of Total revenues7 | |||||||||
| Adjusted EBITDA as a percentage of Total revenues8 | |||||||||
| Earnings per share | |||||||||
| Basic earnings per share | $ | 0.05 | $ | 0.02 | $ | 0.11 | $ | 0.01 | |
| Diluted earnings per share | $ | 0.04 | $ | 0.02 | $ | 0.11 | $ | 0.01 | |
| May 31, 2025 | August 31, 2024 | ||||||||
| Cash | $ | 14,407,569 | $ | 6,620,387 | |||||
| Accounts receivable | 14,087,899 | 13,036,873 | |||||||
| Biological assets | 7,403,862 | 6,649,591 | |||||||
| Inventory | 41,588,100 | 33,423,515 | |||||||
| Working capital9 | 49,385,349 | 40,471,844 | |||||||
| Total assets | 170,087,355 | 154,719,973 | |||||||
| Total current liabilities | 34,616,948 | 27,002,000 | |||||||
| Total non-current liabilities | 36,877,001 | 39,766,484 | |||||||
| Net assets | 98,593,406 | 87,951,489 | |||||||
| Free cash flow for the quarter ended10 | 11,695,142 | 2,693,427 | |||||||
| 1 | Net revenue includes revenue from sale of goods, net of excise taxes and lease revenues. |
| 2 | Adjusted EBITDA is a non-GAAP financial measure. |
| 3 | Gross profit before fair value adjustments as a percentage of Total revenues is a supplementary financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 4 | Gross profit as a percentage of Total revenues is a supplementary financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 5 | Operating income as a percentage of Total revenues is a supplementary financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 6 | Net income before income taxes as a percentage of Total revenues is a supplementary financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 7 | Net income as a percentage of Total revenues is a supplementary financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 8 | Adjusted EBITDA as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 9 | Working capital is a non-GAAP financial measure. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 10 | Free cash flow is a non-GAAP financial measure. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
NON-GAAP MEASURES AND OTHER FINANCIAL MEASURES
The Company reports its financial results in accordance with International Financial Reporting Standards (“IFRS”). Cannara uses a number of financial measures when assessing its results and measuring overall performance. Some of these financial measures are not calculated in accordance with IFRS. National Instrument 52-112 respecting Non-GAAP and Other Financial Measures Disclosure (“NI 52-112”) prescribes disclosure requirements that apply to the following types of measures used by the Company: (i) non-GAAP financial measures and (ii) non-GAAP and other supplementary financial ratios. In this news release, the following non-GAAP measures, non-GAAP and other supplementary financial ratios and segment measures are used by the Company are used by the Company: adjusted EBITDA, free cash flow, working capital, gross profit before fair value adjustments as a percentage of net revenue, gross profit as a percentage of net revenue, operating income as a percentage of net revenue, and adjusted EBITDA as a percentage of net revenue. There are no total of segments measures included in this press release. Additional details for these non-GAAP and other financial measures can be found in the section entitled “Non-GAAP and Other Financial Measures” of Cannara’s MD&A for the three and nine-month periods ended May 31, 2025, which is posted on Cannara’s website at www.cannara.ca and filed on SEDAR+ at www.sedarplus.ca. Reconciliations of non-GAAP financial measures and non-GAAP ratios to the most directly comparable IFRS measures are provided below. Management believes that these non-GAAP financial measures and non-GAAP ratios provide useful information to investors regarding the Company’s financial condition and results of operations as they provide key metrics of its performance. These measures are not recognized under IFRS, do not have any standardized meanings prescribed under IFRS and may differ from similar computations as reported by other issuers, and accordingly may not be comparable. These measures should not be viewed as a substitute for the related financial information prepared in accordance with IFRS.
Reconciliation of Adjusted EBITDA
Adjusted EBITDA is a non-GAAP Measure and can be reconciled with net income, the most directly comparable IFRS financial measure, as detailed below.
Adjusted EBITDA as a percentage of total revenues is a non-GAAP financial ratio, determined as adjusted EBITDA divided by total revenues.
| Three-month periods ended | Nine-month periods ended | ||||||||
| Reconciliation of adjusted EBITDA | May 31, 2025 | May 31, 2024 | May 31, 2025 | May 31, 2024 | |||||
| Net income | $ | 4,142,169 | $ | 2,023,386 | $ | 9,762,573 | 684,045 | ||
| Adjustments: | |||||||||
| Changes in fair value of inventory sold | 6,511,629 | 5,137,341 | 19,285,605 | 17,161,049 | |||||
| Unrealized gain on changes in fair value of biological assets | (7,336,649) | (6,348,550) | (21,630,725) | (15,671,119) | |||||
| Amortization, including amortization in cost of good sold | 1,194,959 | 1,785,153 | 4,240,409 | 4,134,592 | |||||
| Write-down of inventory to net realizable value | 204,596 | 283,244 | 1,035,679 | 1,206,613 | |||||
| Gain on disposal of asset held for sale | - | (2,039,007) | - | (2,039,007) | |||||
| Loss on disposal of property, plant and equipment and right-of-use asset | (1,509) | - | (300) | 5,380 | |||||
| Share-based compensation | 262,772 | 404,172 | 879,344 | 1,616,878 | |||||
| Net finance expense | 972,377 | 1,530,658 | 3,318,384 | 4,349,098 | |||||
| Income taxes | 1,650,181 | - | 3,793,075 | - | |||||
| Adjusted EBITDA* | $ | 7,600,525 | $ | 2,776,397 | $ | 20,684,044 | $ | 11,447,529 | |
| Adjusted EBITDA as a percentage of Total revenues ** | |||||||||
| *Non-GAAP financial measure | |||||||||
| **Non-GAAP financial ratio | |||||||||
NON-GAAP MEASURES, NON-GAAP RATIOS AND SEGMENT MEASURES
Reconciliation of free cash flow
Free cash flow is a non-GAAP measure and can be reconciled with Cash from operating activities, the most directly comparable IFRS financial measure, as detailed below.
| Three-month periods ended | Nine-month periods ended | ||||||||
| Reconciliation of free cash flow | May 31, 2025 | May 31, 2024 | May 31, 2025 | May 31, 2024 | |||||
| Cash from operating activities | $ | 13,901,855 | $ | 4,325,380 | $ | 17,186,288 | $ | 7,496,392 | |
| Adjustment: | |||||||||
| Capital expenditures | 2,206,713 | 3,082,853 | 4,892,715 | 6,975,869 | |||||
| Free cash flow* | $ | 11,695,142 | $ | 1,242,527 | $ | 12,293,573 | $ | 520,523 | |
| *Non-GAAP financial measure | |||||||||
Reconciliation of working capital
Working capital is a non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable IFRS financial measure, as detailed below.
| Reconciliation of working capital | As at May 31, 2025 | As at August 31, 2024 | ||
| Total current assets | $ | 84,002,297 | $ | 67,473,844 |
| Total current liabilities | 34,616,948 | 27,002,000 | ||
| Working capital* | $ | 49,385,349 | $ | 40,471,844 |
| *Non-GAAP financial measure | ||||
PREVIOUSLY DISCLOSED QUARTERLY EVENTS
June 2025 – Brand of the Year Award
On June 18, 2025, the Company announced it had been honoured with two awards at the 6th Annual Grow Up Awards Gala held in Toronto on May 28, 2025. The Company’s Tribal brand was named Brand of the Year, and its Nugz Häpple product was awarded the Accessory of the Year prize. The Grow Up Awards Gala is a nationally recognized event celebrating outstanding achievement in the Canadian cannabis industry
June 2025 – Reduced Interest Rate on BMO Credit Facility
On June 18, 2025, the Company announced it had completed an agreement to amend and restate its existing credit agreement with BMO acting as administrative agent, lead arranger, syndication agent and sole bookrunner (the “Restated Credit Facility”) to obtain a total reduction of 50 basis points in the interest rate spread. This reduction was achieved in two stages: an initial 25 basis point decrease secured through an amendment to the credit agreement, followed by an additional 25 basis point reduction triggered by the Company’s successful achievement of certain covenant thresholds as of Q2 2025 (ended February 28, 2025). As a result, Cannara’s overall cost of debt on its credit facility reduced from over
Subsequent to quarter-end, the Company achieved a further 25 basis point interest rate reduction after meeting key covenant thresholds as of Q3 2025, resulting in the full additional savings to be realized in reduced interest expense going forward.
In addition, as of March 2025, the Company successfully met key covenant thresholds under its credit agreement with BMO, eliminating the need for the limited recourse guarantee previously provided by a related party. This milestone reduced annual interest expense by
A copy of the Restated Credit Facility has been filed under the Company’s profile on SEDAR+ at www.sedarplus.ca.
June 2025 – Olymbec Convertible Debenture Repayment
On June 18, 2025, the Company concurrently announced it had made a
A copy of the Olymbec Convertible Debenture (as amended and restated) has been filed under the Company’s profile on SEDAR+ at www.sedarplus.ca.
CAPITAL TRANSACTIONS AND OTHER EVENTS
Capital Transactions
During Q3 2025, the Company granted 100,000 stock options at an exercise price of
Subsequent to quarter-end, the Company granted 7,500 stock options at an exercise price of
CONTACT
| Nicholas Sosiak, CPA, CA Chief Financial Officer nick@cannara.ca | Zohar Krivorot President & Chief Executive Officer zohar@cannara.ca |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ABOUT CANNARA
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.
CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION
This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.
In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.
Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.
FAQ
What were Cannara Biotech's (LOVFF) Q3 2025 revenue and earnings?
How much did Cannara's Adjusted EBITDA grow in Q3 2025?
What was Cannara's market share in Quebec for Q3 2025?
How much did Cannara's production capacity increase in Q3 2025?
What is Cannara's position in Quebec's new vape category?
